GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Launched by SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jun 22, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new type of treatment called CAR-T cell therapy, which is designed to help fight various types of cancer, including lung cancer. In this trial, researchers have developed special CAR-T cells that target specific proteins found on certain cancer cells. The goal is to see how safe and effective these cells are when used in patients whose cancers express these proteins. This is the first phase of the study, focusing on understanding how well these CAR-T cells work in treating cancer and ensuring that they are safe for patients.

To be eligible for this trial, patients should have advanced cancer that shows certain proteins on their cells, a life expectancy of more than 12 weeks, and good functioning of their heart, lungs, liver, and kidneys. Participants will receive the CAR-T cell treatment and will be closely monitored for any side effects and how well the therapy works. It's important for patients to understand the details of the study and provide informed consent before participating. If you or someone you know is considering this treatment, it could be a promising option to explore.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with advanced cancer that expresses GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR protein; 2. Life expectancy \>12 weeks; 3. Adequate heart,lung,liver,kidney function; 4. Available autologous transduced T cells with greater than or equal to 20% expression ofGPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR-CAR determined by flow-cytometry and killing of GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR-positive targets greater than or equal to 20% in cytotoxicity assay; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
• • -
• Exclusion Criteria:
• • 1. Had accepted gene therapy before;
• • 2. Severe virus infection such as HBV,HCV,HIV,et al;
• • 3. Known HIV positivity;
• • 4. Active infectious disease related to bacteria, virus,fungi,et al;
• • 5. Other severe diseases that the investigators consider not appropriate;
• • 6. Pregnant or lactating women;
• • 7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
• • 8. Other conditions that the investigators consider not appropriate. -